Sodium and Water Balance

Extracellular fluid volume (ECFV) is the total amount of fluid outside cells — plasma plus interstitial fluid — and it is determined almost entirely by the total amount of sodium in the body, because sodium is the major extracellular solute and water passively follows it osmotically. If you retain sodium, you retain water with it, in isosmotic proportion, and ECFV expands without a change in concentration. If you lose sodium, you lose water with it, and ECFV contracts, again without much change in concentration. Volume regulation is therefore accomplished physiologically by regulating sodium excretion, not water excretion. The kidney adjusts how much of the filtered sodium load it reabsorbs, and water tags along.

Osmolarity is the concentration of solutes dissolved in body fluids, expressed in milliosmoles per liter, with a normal plasma value of about 280–296 mOsm/L. Osmolarity changes when the ratio of solute to water shifts — drinking pure water dilutes it, sweating without replacing water concentrates it — independent of whether total volume has changed much. Osmolarity regulation is accomplished by regulating water excretion and water intake (via Regulation of Body Fluid Osmolarity mechanisms: vasopressin and thirst), not sodium excretion, because water can be added or removed from the body fluid compartment without net solute being added or removed, directly diluting or concentrating whatever solute is already there. The critical conceptual move is recognizing that these two variables — total volume and concentration — are mathematically and physiologically separable, even though they are both properties of the same body fluid. A person can be volume-depleted with normal osmolarity (hemorrhage), volume-expanded with normal osmolarity (excess isotonic saline infusion), volume-normal with low osmolarity (drinking too much water), or volume-normal with high osmolarity (fever with insensible water loss but adequate salt intake). Each of these four states requires a different corrective reflex, and the body has built two parallel but non-identical control systems — one keyed to sodium/volume, one keyed to water/osmolarity — precisely so it can respond appropriately to each.

Step 1 — Two separate classes of sensor. Osmolarity is sensed by osmoreceptor neurons in the hypothalamus, concentrated in the organum vasculosum of the lamina terminalis (OVLT) and nearby circumventricular organs that lie outside the blood-brain barrier. These cells shrink or swell as plasma osmolarity rises or falls, changing their firing rate through stretch-inactivated cation channels; a rise of even 1–2% in plasma osmolarity (roughly 3 mOsm/L) is detectable and triggers both thirst and vasopressin release from the hypothalamic supraoptic and paraventricular nuclei. This system is exquisitely sensitive but responds to concentration, not to how much total fluid there is. Volume is sensed by an entirely different anatomical set: mechanoreceptors that respond to stretch caused by the pressure or fullness of fluid compartments. Because the body cannot directly "measure liters" of extracellular fluid, it infers volume indirectly from the pressure that volume generates in the vasculature.

Step 2 — Volume sensing triggers sodium-retaining effectors. A fall in effective circulating volume (from hemorrhage, dehydration, or heart failure) reduces stretch on cardiac and arterial baroreceptors. This reduces afferent vagal and glossopharyngeal inhibitory signaling to the medullary cardiovascular centers, which in turn increases sympathetic outflow. Sympathetic nerves acting directly on the kidney increase renin release from juxtaglomerular cells and constrict the afferent arteriole, cutting glomerular filtration rate and thus filtered sodium load. Falling renal perfusion pressure itself, sensed by the JGA as reduced stretch of the afferent arteriole, is an independent trigger for renin release, as is reduced NaCl delivery to the macula densa (interpreted by the kidney as low flow). Renin cleaves angiotensinogen to angiotensin I, converted by ACE (mainly in pulmonary capillaries) to angiotensin II, which:

• constricts systemic arterioles, raising arterial pressure directly;
• stimulates the adrenal cortex (zona glomerulosa) to secrete aldosterone, which upregulates epithelial sodium channels (ENaC) and Na⁺/K⁺-ATPase in the cortical collecting duct, increasing sodium reabsorption;
• stimulates thirst and (mildly) vasopressin release as an ancillary effect;
• promotes proximal tubule sodium reabsorption directly.

The net effect of all these arms — sympathetic renal vasoconstriction, reduced GFR, and aldosterone-driven distal sodium reabsorption — is near-total renal sodium conservation, sometimes reducing urinary sodium excretion to below 5 mEq/day in severe volume depletion. Because water follows sodium osmotically in the proximal tubule and collecting duct, volume is restored without a large independent change in osmolarity. This whole hormonal cascade is elaborated further as the Renin-Angiotensin-Aldosterone System. Opposing this system, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are released from stretched atrial and ventricular myocardium when volume expands. They inhibit renin release, antagonize aldosterone's action, dilate the afferent arteriole while constricting the efferent arteriole (raising GFR), and directly reduce sodium reabsorption in the collecting duct — producing natriuresis that offloads excess volume.

Step 3 — Osmolarity sensing triggers water-selective effectors. A rise in plasma osmolarity — say from sweating without replacing fluid — shrinks OVLT osmoreceptor neurons, increasing their firing. This does two things nearly simultaneously: it drives the sensation of thirst (behavioral effector, increasing water intake) and it stimulates magnocellular neurons of the supraoptic and paraventricular nuclei to release vasopressin (antidiuretic hormone, ADH) from the posterior pituitary. ADH binds V2 receptors on the basolateral membrane of collecting duct principal cells, triggering a Gs-cAMP-PKA cascade that causes cytoplasmic vesicles containing aquaporin-2 water channels to fuse with the apical membrane. Water — but essentially no sodium — is then reabsorbed down the osmotic gradient established by the countercurrent multiplier in the medulla, concentrating the urine and diluting the blood back toward normal. Critically, this pathway changes body water content and thus osmolarity, while barely touching total body sodium — a person can correct hyperosmolarity by retaining water alone, without any change in the sodium-retention machinery described above. Conversely, drinking excess water suppresses ADH secretion (osmoreceptors shrink less; they even hyperpolarize slightly), aquaporin-2 channels are internalized, the collecting duct becomes impermeable to water, and dilute urine (as low as 50 mOsm/L) is excreted — again without engaging the renin-angiotensin-aldosterone axis at all, because total volume hasn't changed much (water and sodium disturbances of this kind are usually modest relative to the ~40 L of total body water).

Step 4 — What happens when the two signals conflict. The clearest test of the system's priorities comes during severe hemorrhage. Blood volume falls sharply, but osmolarity is essentially unchanged (whole blood is lost, not just water). Strict osmolarity logic would predict no change in ADH secretion. But baroreceptor unloading is such a powerful non-osmotic stimulus for vasopressin release that large falls in blood pressure or volume (>10–15%) override the osmoreceptor set point, driving ADH secretion to levels many times higher than any osmotic stimulus could produce. This is a volume signal borrowing the osmolarity effector (ADH/water conservation) as an emergency backup to defend blood pressure, even at the cost of temporarily diluting the blood. Vascular volume restoration takes precedence, because inadequate perfusion pressure threatens survival on a timescale of minutes, whereas mild hyponatremia is tolerated for hours.

Gauer, Henry, and Sieker (1954, and follow-up studies through the 1960s) established that the atria themselves — not just arterial baroreceptors — are volume sensors. They inflated small balloons in the left atria of anesthetized dogs to mimic increased venous return without changing arterial pressure, and observed a prompt, reversible diuresis. Cutting the vagal afferents from the atria abolished this diuretic response to atrial distension. This proved that low-pressure cardiopulmonary receptors, independent of the arterial baroreceptor system, feed directly into renal fluid-handling reflexes — the anatomical basis for the volume-sensing arm described above, and part of what led to the search for a circulating natriuretic substance.

Discovery of atrial natriuretic peptide — de Bold and colleagues (1981). Adolfo de Bold injected crude extracts of rat atrial tissue (but not ventricular tissue) into rats and observed a massive, rapid natriuresis and diuresis — urinary sodium excretion increased manyfold within minutes. Ventricular extracts had almost no effect. This experiment identified the heart itself as an endocrine organ producing a hormone (later purified and sequenced as ANP) that directly senses its own stretch and opposes the aldosterone system — completing the volume-regulation circuit with both an accelerator (renin-angiotensin-aldosterone) and a brake (natriuretic peptides).

Verney's classic osmoreceptor experiments (1947). Ernest Verney infused hypertonic saline into the carotid artery of dogs — reaching the hypothalamus before dilution by the systemic circulation — and observed an immediate, marked antidiuresis (reduced urine flow, concentrated urine), even though no change in total body water or blood volume had occurred systemically. Infusing an equivalent amount of hypertonic saline into a peripheral vein (allowing it to dilute in the whole circulation) produced a far smaller effect. Verney further showed that infusing an isosmotic solution of urea (which crosses cell membranes freely and thus does not create an effective osmotic gradient) produced no antidiuresis at all, despite raising numerical osmolarity — proving the receptor detects effective, not just total, osmotic pressure, and that it is anatomically localized near the hypothalamic circulation rather than distributed throughout the vascular tree. This was the founding demonstration that osmolarity is sensed by a discrete neural population, separate from the volume-sensing baroreceptors, and it is the direct ancestor of modern osmoreceptor physiology.

Clinical confirmation — Schwartz and Bartter's description of SIADH (1957). Schwartz and colleagues described patients with bronchogenic carcinoma who had persistently high plasma ADH and progressive hyponatremia despite normal or expanded extracellular volume — proving that ADH secretion (and hence water balance) can become uncoupled from the volume-regulation axis entirely. Because these patients were not volume-depleted, their renin-angiotensin-aldosterone axis was appropriately suppressed, yet inappropriate ADH secretion continued to drive water retention and dilutional hyponatremia — clean clinical evidence that the two systems are genuinely separable, not just theoretically distinct, and that one can fail while the other functions normally.

Example 1 — Distinguishing the two disorders by the numbers. A 68-year-old man on furosemide (a loop diuretic that blocks sodium reabsorption in the thick ascending limb) develops the following labs after several days of poor oral intake:

Reasoning: the low blood pressure, tachycardia, and very low urine sodium (near-total renal sodium conservation) indicate the volume-sensing system has been activated appropriately — baroreceptors detect true hypovolemia (from diuretic-induced sodium and water loss combined with poor intake) and have driven maximal renin-angiotensin-aldosterone activity, explaining urine Na⁺ of 8 mEq/L. But plasma osmolarity is also low — this is because the non-osmotic (baroreceptor-driven) stimulus to ADH has overridden the osmoreceptor system, causing water retention that dilutes the plasma sodium despite the low osmolarity that would normally suppress ADH. This is hypovolemic hyponatremia: the volume system is winning, and correcting it requires isotonic (not hypotonic, and not pure free-water-restricted) saline to restore volume, which will simultaneously shut off the inappropriate ADH drive and allow the excess free water to be excreted. Contrast this with a psychiatric inpatient who drinks 6 liters of water in an afternoon (primary polydipsia): plasma Na⁺ might fall to 128 mEq/L too, but blood pressure and heart rate would be normal, and urine sodium would not be driven toward zero, because the volume-sensing system was never triggered — only osmolarity fell, appropriately suppressing ADH (though transiently overwhelmed by intake volume) and producing dilute urine as the kidney tries to excrete the excess water. Same plasma sodium number, two entirely different mechanisms, two entirely different treatments (fluid restriction, not saline).

Example 2 — Quantitative volume vs. osmotic contribution after sweat loss. A marathon runner loses 3 L of sweat, which is hypotonic relative to plasma (roughly 50 mEq Na⁺/L, versus plasma's ~140 mEq/L), and replaces the loss entirely with 3 L of plain water over the race. Sodium lost: 3 L × 50 mEq/L = 150 mEq Na⁺ lost, not replaced (since only water was drunk). Before the run, assume total body water ≈ 42 L, total body Na⁺ (extracellular pool, simplified) contributing to an effective osmolarity of 285 mOsm/L. Net effect: total body water is roughly restored (3 L lost, 3 L drunk), so ECFV is approximately maintained — the volume-sensing system sees only a mild disturbance. But 150 mEq of sodium has been lost without replacement, while water has been fully replaced, so the concentration of remaining sodium in the body fluid is now lower: the osmoreceptor system detects a fall in effective osmolarity and suppresses ADH, appropriately promoting water excretion to concentrate the remaining fluid back toward 285 mOsm/L. This scenario — replacing sweat losses with plain water rather than an electrolyte solution — is precisely why endurance athletes are at risk of exercise-associated hyponatremia: the osmolarity system pushes toward water excretion, but if intake continues to outpace excretion (drinking faster than the kidney's maximum free-water clearance, which is limited under exercise-associated ADH release from concurrent volume/stress stimuli), plasma sodium falls dangerously despite a nearly normal total volume. This is the mechanistic argument for electrolyte-containing sports drinks over plain water during prolonged exertion.

Verney trained as a physician and served in both World Wars before turning to systematic experimental physiology on fluid balance at University College London. Working with dogs under careful anesthesia, he developed the technique of infusing solutions directly into a carotid artery cannula aimed at the brain, exploiting the short circulatory path from carotid to hypothalamus to test whether the brain itself, rather than peripheral tissues or the kidney, was sensing plasma tonicity. His 1947 Croonian Lecture to the Royal Society, "The Antidiuretic Hormone and the Factors Which Determine Its Release," laid out the osmoreceptor concept with a rigor that has changed remarkably little in the roughly eight decades since. He was among the first physiologists to insist — against a then-common assumption that the kidney alone "decided" how much water to excrete based on its own filtration load — that a discrete central sensor upstream of the kidney was doing the deciding, and that the kidney was merely executing instructions from the brain.

Emergency and critical care medicine rests on this distinction: the initial resuscitation fluid for a trauma patient in hemorrhagic shock is isotonic crystalloid or blood products (restoring volume), never free water or hypotonic fluid, because volume — not osmolarity — is the immediately life-threatening deficit. Conversely, a patient with diabetes insipidus (failure of the osmolarity axis due to inadequate ADH or renal unresponsiveness to it) is treated with desmopressin or free water, not saline.

Nephrology and the diagnosis of hyponatremia use volume status (assessed clinically, plus urine sodium and urine osmolarity) as the first branch point in every diagnostic algorithm, precisely because the same plasma sodium number can arise from opposite underlying mechanisms requiring opposite treatments — as worked through in Example 1.

Cardiology and heart failure management exploit the volume axis directly: loop diuretics, aldosterone antagonists (spironolactone, eplerenone), and ACE inhibitors/ARBs all target the renin-angiotensin-aldosterone side of the system to relieve fluid overload, while recombinant BNP (nesiritide) and neprilysin inhibitors (sacubitril) amplify the natriuretic peptide brake.

Sports medicine and endurance athletics apply the osmolarity axis: understanding that plain water replacement during prolonged exercise can outpace the kidney's capacity to excrete free water (especially when exercise-related non-osmotic ADH release is superimposed), guiding recommendations for sodium-containing rehydration fluids to prevent exercise-associated hyponatremic encephalopathy, a rare but documented cause of death in marathon and ultra-endurance events.

Agriculture and veterinary medicine apply the same volume/osmolarity logic in managing dehydration and electrolyte disorders in livestock, and in formulating oral rehydration solutions for diarrheal disease in both animals and — critically in global public health — in children, where the WHO oral rehydration solution is precisely tuned in sodium and glucose concentration to restore volume via sodium-glucose cotransport while avoiding the dangers of pure water rehydration.

Ask the tutor: How does the kidney's medullary countercurrent multiplier actually generate the osmotic gradient that ADH exploits to concentrate urine?